Area of research
Cardiology and Cardiovascular Medicine · Endocrinology, Diabetes and Metabolism
Research interest
Research interests include Heart Failure Treatment and Management, Cardiovascular Function and Risk Factors, Hormonal Regulation and Hypertension, and Atrial Fibrillation Management and Outcomes.
Clinical Management and Therapeutic Optimization of Patients with Heart Failure with Reduced Ejection Fraction and Low Blood Pressure. A Clinical Consensus Statement of the Heart Failure Association (HFA) of the ESC
Heart Failure and Obesity: Translational Approaches and Therapeutic Perspectives. A Scientific Statement of the Heart Failure Association of the ESC
Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis
Echocardiographic and biomarker characteristics in diabetes, coronary artery disease or both: insights from HOMAGE trial
Adherence to Guideline-Directed Medical Treatments in Heart Failure. A Scientific Statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Cardiovascular Pharmacotherapy
Association between ultra-processed food consumption and inflammation: insights from the STANISLAS cohort
Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction
Pharmacological Treatment for Patients with Obesity and Heart Failure: Focus on Glucagon-Like Peptide-1 Receptor Agonists. <i>European Journal of Heart Failure</i> Expert Consensus Document
Characteristics and Outcomes of Patients with Heart Failure and History of Malignancy: Data from Swedish Heart Failure Registry and the National Cancer Register
How to Tackle Therapeutic Inertia in Heart Failure with Reduced Ejection Fraction. A Scientific Statement of the Heart Failure Association of the ESC
Machine Learning Approach to Identify Phenotypes in Patients with Ischaemic Heart Failure with Reduced Ejection Fraction
Lung ultrasound in acute and chronic heart failure: a clinical consensus statement of the European Association of Cardiovascular Imaging (EACVI)
Protein Biomarkers of New-Onset Heart Failure: Insights From the Heart Omics and Ageing Cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study
Diuretic Dose is a Strong Prognostic Factor in Ambulatory Patients Awaiting Heart Transplantation
Time to Clinical Benefit of Eplerenone Among Patients with Heart Failure and Reduced Ejection Fraction: A Subgroups Analysis from the EMPHASIS-HF Trial
Effect of Spironolactone on QRS Duration in Patients at Risk for Heart Failure (from the HOMAGE Trial)
Effect of Moderate Hypothermia vs Normothermia on 30-Day Mortality in Patients With Cardiogenic Shock Receiving Venoarterial Extracorporeal Membrane Oxygenation
Practical outpatient management of worsening chronic heart failure
Therapeutic Inertia in the Pharmacological Management of Heart Failure with Reduced Ejection Fraction
Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fraction
Fatty acid desaturase genetic variations and dietary omega-3 fatty acid intake associate with arterial stiffness
Sequencing and Titrating Approach of Therapy in Heart Failure with Reduced Ejection Fraction Following the 2021 European Society of Cardiology Guidelines: An International Cardiology Survey
Timing of Statistical Benefit of Mineralocorticoid Receptor Antagonists Among Patients With Heart Failure and Post-Myocardial Infarction
Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the <scp>HOMAGE</scp> trial
Comparing and contrasting risk factors for heart failure in patients with and without history of myocardial infarction: data from <scp>HOMAGE</scp> and the <scp>UK</scp> Biobank
Early and late renal function changes with spironolactone in patients at risk of developing heart failure: findings from the HOMAGE trial
Dyskalemia in People at Increased Risk for Heart Failure: Findings from the Heart ‘OMics’ in AGEing (HOMAGE) Trial
Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF
Urinary peptides in heart failure: a link to molecular pathophysiology
Identification of Sex-Specific Biomarkers Predicting New-Onset Heart Failure